Both Roswell Park Comprehensive Cancer Center (RPCI) and the University of Pittsburgh Cancer Institute (UPCI) have long-standing commitments to academic excellence and groundbreaking cancer research, and both employ rich intellectual, technological, and financial resources to pursue comprehensive, collaborative research programs involving large numbers of renowned scientists and clinicians. The two institutions are well qualified to perform extraordinary translational research in ovarian cancer and achieve the fundamental goals of the SPORE initiative. Both facilities have attracted substantial expertise in the field of ovarian cancer and understand the value of multidisciplinary translational research.
Roswell Park Comprehensive Cancer Center
RPCI is America's first cancer center founded in 1898 by Dr. Roswell Park. His revolutionary model of a multidisciplinary approach to cancer — with scientists and clinicians working in concert and in consult — has become the standard by which all modern-day comprehensive cancer centers are measured.
RPCI is the first and only upstate New York facility to hold the National Cancer Institute (NCI) designation of Comprehensive Cancer Center and to serve as a member of the prestigious National Comprehensive Cancer Network (NCCN). Many RPCI faculty serve on the NCCN panels that create the Clinical Practice Guidelines in OncologyTM – the internationally recognized standards for clinical policy in oncology, and the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine.
Over its long history, Roswell Park Comprehensive Cancer Center has made fundamental contributions to reducing the cancer burden and has successfully maintained an exemplary leadership role in setting the national standards for cancer care, research and education.
Over the last decade, RPCI has undergone major growth, adding over 1,000 new jobs, initiating one of the nation’s first hospital facilities dedicated to Phase I cancer research studies, and setting itself apart as a leader in surgical robotics, vitamin D research, immunotherapy and vaccine therapy, studies targeting tumor microenvironment and cancer prevention, and the development and testing of new agents and technology. Committing the infrastructure, intellectual capital and necessary resources to convert its scientific discoveries into products/applications, RPCI has established a number of biotech spin-off companies, and formed strategic partnerships with investigators and centers throughout the world.
The campus spans 25 acres in downtown Buffalo, New York and consists of 15 buildings with about 1.6 million square feet of space. A new hospital building, completed in 1998, houses a comprehensive diagnostic and treatment center. In addition, the Institute built a new medical research complex and renovated existing education and research space to support its future growth and expansion.
University of Pittsburgh Cancer Institute
Founded in 1985, UPCI is the only NCI-designated Comprehensive Cancer Center in western Pennsylvania. With more than 350 research and clinical faculty members specializing in disciplines ranging from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end of life care, UPCI maintains a broad strategic vision and comprehensive approach to understanding and defeating cancer. In 2011, UPCI received nearly $174 million in research grants, and was ranked 12th nationally in funding from the NCI.
UPCI investigators are leaders in molecular and medical oncology, spearheading innovative research studies to:
- Advance our understanding of the biological basis of cancer development and progression
- Identify new and relevant biomarkers for improved cancer detection and diagnosis
- Develop novel therapeutics for successful and comprehensive cancer treatment
- Establish and implement effective measures for cancer prevention
While most UPCI faculty maintain academic appointments at the University of Pittsburgh, some UPCI members are affiliated with neighboring institutions, including Carnegie Mellon University and University of Pittsburgh Medical Center (UPMC) Hospitals.
At UPCI, basic researchers collaborate with clinician-scientists to rapidly advance the most promising laboratory studies into novel clinical trials, providing patients with early access to new and innovative treatments both at the Hillman Cancer Center and throughout the network of UPMC CancerCenter sites. Currently, patients have access to hundreds of clinical trials at UPCI and UPMC CancerCenter.
Sustained by the ongoing recruitment of internationally renowned scientists, increases in funding, and planned expansion of laboratory and clinical space, UPCI continues to grow and evolve, making vast strides in its quest to significantly reduce the burden of cancer.